NCT06746519 - BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

December 25, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2027

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine

The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

collaborator

BioNova Pharmaceuticals (Shanghai) LTD.

INDUSTRY

lead

Chen Suning

OTHER